590 related articles for article (PubMed ID: 11099897)
1. Transfusional iron overload and chelation therapy with deferoxamine and deferiprone (L1).
Kontoghiorghes GJ; Pattichi K; Hadjigavriel M; Kolnagou A
Transfus Sci; 2000 Dec; 23(3):211-23. PubMed ID: 11099897
[TBL] [Abstract][Full Text] [Related]
2. Benefits and risks of deferiprone in iron overload in Thalassaemia and other conditions: comparison of epidemiological and therapeutic aspects with deferoxamine.
Kontoghiorghes GJ; Neocleous K; Kolnagou A
Drug Saf; 2003; 26(8):553-84. PubMed ID: 12825969
[TBL] [Abstract][Full Text] [Related]
3. Present status and future prospects of oral iron chelation therapy in thalassaemia and other diseases.
Kontoghiorghes GJ
Indian J Pediatr; 1993; 60(4):485-507. PubMed ID: 8262586
[TBL] [Abstract][Full Text] [Related]
4. Desferrioxamine mesylate for managing transfusional iron overload in people with transfusion-dependent thalassaemia.
Fisher SA; Brunskill SJ; Doree C; Gooding S; Chowdhury O; Roberts DJ
Cochrane Database Syst Rev; 2013 Aug; (8):CD004450. PubMed ID: 23963793
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of iron-chelation therapy with deferoxamine, deferiprone, and deferasirox for the treatment of iron-loaded patients with non-transfusion-dependent thalassemia syndromes.
Kontoghiorghe CN; Kontoghiorghes GJ
Drug Des Devel Ther; 2016; 10():465-81. PubMed ID: 26893541
[TBL] [Abstract][Full Text] [Related]
6. Effective new treatments of iron overload in thalassaemia using the ICOC combination therapy protocol of deferiprone (L1) and deferoxamine and of new chelating drugs.
Kontoghiorghes GJ; Kolnagou A
Haematologica; 2006 Jun; 91(6 Suppl):ELT04. PubMed ID: 16785141
[TBL] [Abstract][Full Text] [Related]
7. Oral deferiprone for iron chelation in people with thalassaemia.
Fisher SA; Brunskill SJ; Doree C; Chowdhury O; Gooding S; Roberts DJ
Cochrane Database Syst Rev; 2013 Aug; (8):CD004839. PubMed ID: 23966105
[TBL] [Abstract][Full Text] [Related]
8. Deferiprone: a review of its clinical potential in iron overload in beta-thalassaemia major and other transfusion-dependent diseases.
Barman Balfour JA; Foster RH
Drugs; 1999 Sep; 58(3):553-78. PubMed ID: 10493280
[TBL] [Abstract][Full Text] [Related]
9. A risk-benefit assessment of iron-chelation therapy.
Porter JB
Drug Saf; 1997 Dec; 17(6):407-21. PubMed ID: 9429839
[TBL] [Abstract][Full Text] [Related]
10. Comparison between deferoxamine and deferiprone (L1) in iron-loaded thalassemia patients.
Taher A; Sheikh-Taha M; Koussa S; Inati A; Neeman R; Mourad F
Eur J Haematol; 2001 Jul; 67(1):30-4. PubMed ID: 11553264
[TBL] [Abstract][Full Text] [Related]
11. Interventions for improving adherence to iron chelation therapy in people with sickle cell disease or thalassaemia.
Fortin PM; Fisher SA; Madgwick KV; Trivella M; Hopewell S; Doree C; Estcourt LJ
Cochrane Database Syst Rev; 2018 May; 5(5):CD012349. PubMed ID: 29737522
[TBL] [Abstract][Full Text] [Related]
12. New chelation therapies and emerging chelating drugs for the treatment of iron overload.
Kontoghiorghes GJ
Expert Opin Emerg Drugs; 2006 Mar; 11(1):1-5. PubMed ID: 16503822
[TBL] [Abstract][Full Text] [Related]
13. Iron chelation therapy.
Hoffbrand AV; Wonke B
J Intern Med Suppl; 1997; 740():37-41. PubMed ID: 9350180
[TBL] [Abstract][Full Text] [Related]
14. Prevention of Iron Overload and Long Term Maintenance of Normal Iron Stores in Thalassaemia Major Patients using Deferiprone or Deferiprone Deferoxamine Combination.
Kolnagou A; Kontoghiorghe CN; Kontoghiorghes GJ
Drug Res (Stuttg); 2017 Jul; 67(7):404-411. PubMed ID: 28320041
[TBL] [Abstract][Full Text] [Related]
15. Clinical use, therapeutic aspects and future potential of deferiprone in thalassemia and other conditions of iron and other metal toxicity.
Kontoghiorghes GJ
Drugs Today (Barc); 2001 Jan; 37(1):23-35. PubMed ID: 12783095
[TBL] [Abstract][Full Text] [Related]
16. New concepts of iron and aluminium chelation therapy with oral L1 (deferiprone) and other chelators. A review.
Kontoghiorghes GJ
Analyst; 1995 Mar; 120(3):845-51. PubMed ID: 7741239
[TBL] [Abstract][Full Text] [Related]
17. [Iron chelation in 1998].
de Montalembert M
Transfus Clin Biol; 1998 Oct; 5(5):353-6. PubMed ID: 9836396
[TBL] [Abstract][Full Text] [Related]
18. Advances in iron overload therapies. prospects for effective use of deferiprone (L1), deferoxamine, the new experimental chelators ICL670, GT56-252, L1NA11 and their combinations.
Kontoghiorghes GJ; Eracleous E; Economides C; Kolnagou A
Curr Med Chem; 2005; 12(23):2663-81. PubMed ID: 16305464
[TBL] [Abstract][Full Text] [Related]
19. Chelation protocols for the elimination and prevention of iron overload in thalassaemia.
Kolnagou A; Kontoghiorghes GJ
Front Biosci (Landmark Ed); 2018 Jan; 23(6):1082-1098. PubMed ID: 28930590
[TBL] [Abstract][Full Text] [Related]
20. Pharmacotherapy of iron overload in thalassaemic patients.
Ceci A; Felisi M; De Sanctis V; De Mattia D
Expert Opin Pharmacother; 2003 Oct; 4(10):1763-74. PubMed ID: 14521486
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
